Form SC 13G/A Q32 Bio Inc. Filed by: Temasek Holdings (Private) Ltd
Q32 Bio Inc. (QTTB)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
QTTB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QTTB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QTTB alerts
High impacting Q32 Bio Inc. news events
Weekly update
A roundup of the hottest topics
QTTB
News
- Q32 Bio Inc. (NASDAQ: QTTB) had its price target lowered by analysts at Wells Fargo & Company from $16.00 to $15.00. They now have an "equal weight" rating on the stock.MarketBeat
- Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate UpdatePR Newswire
- Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology MeetingPR Newswire
- Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting [Yahoo! Finance]Yahoo! Finance
QTTB
Earnings
- 3/11/25 - Beat
QTTB
Sec Filings
- 3/11/25 - Form S-8
- 3/11/25 - Form 424B3
- 3/11/25 - Form 10-K
- QTTB's page on the SEC website